Is ESLOY a Good Stock to Buy? The Bull and Bear Case (2026)

Last updated November 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for EssilorLuxottica (ESLOY) rests on AI glasses and the Meta partnership: Wearables, mainly Ray-Ban Meta and Oakley Meta glasses plus Nuance Audio, brought in ~€1.26 billion over the first nine months of 2026 and ~€486 million in the third quarter alone, now about 6.5% of quarterly revenue. The bear case rests on wearables are the largest swing factor. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

ESLOY key stats

At $95.06 on November 20, 2026, EssilorLuxottica (ESLOY) has a market cap of $87.2B, a P/E of 30.5 on trailing earnings (21.4 on forward earnings) and a dividend yield of 2.44%.

Market cap
$87.2B
P/E (trailing)
30.5
P/E (forward)
21.4
EPS (trailing 12 months)
$3.12
Price to book
2.0
Dividend yield
2.44%
Beta
0.54

Market cap, P/E and yield are measured at the $95.06 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with EssilorLuxottica (ESLOY)?

The last two weeks for EssilorLuxottica, as of November 22, 2026: the price move, the next earnings date, and what analysts changed.

  • ESLOY closed at $95.06 on November 20, 2026, down 5.5% over the past five trading days (from $100.55).

Prices are daily closes from Yahoo Finance. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

EssilorLuxottica is the world's largest eyewear company. It was formed in 2018 when French lens maker Essilor merged with Italian frame maker Luxottica, and it now covers almost every step between an eye exam and a pair of glasses. It designs and makes prescription lenses (Varilux, Crizal, Transitions, Stellest for children's myopia), owns frame and sunglass brands such as Ray-Ban, Oakley, Persol and Oliver Peoples, makes licensed frames for Chanel, Prada and others, and runs retail chains including LensCrafters, Sunglass Hut, Target Optical in the US and Salmoiraghi & Viganò in Italy. Through its partnership with Meta it also makes Ray-Ban Meta and Oakley Meta AI glasses, and it sells Nuance Audio hearing glasses. ESLOY is a sponsored ADR on the OTC market: one ADR represents half an ordinary share listed in Paris under EL, and it trades in US dollars while the company reports in euros. Revenue for 2025 was ~€28.5 billion, up 11.2% at constant currency, though adjusted operating margin slipped to ~15.7% as the company spent on AI glasses, R&D and medtech. 2026 has gone better on margins. First-half revenue rose 9.7% at constant currency to ~€14.8 billion and adjusted operating profit grew ~15%, for a margin of ~18.6%. Third-quarter revenue, reported on October 20, came to ~€7.49 billion, up 7.2% at constant currency and above the ~€7.36 billion analysts expected. Direct-to-consumer sales grew 10.6%, Asia-Pacific grew 15.7%, myopia management grew 24%, and wearables reached ~€486 million, up 20%, a sharp slowdown from the near doubling in the second quarter. The stock has been volatile. The Paris shares fell from a record above €320 in late 2025 to a low near €138 in 2026 on worries about AI glasses competition from Google and Apple, slower wearables growth and thinner margins, then jumped about 14% the day after the third-quarter beat. That bounce has since faded: ESLOY closed at ~$95.79 on November 20, 2026, down 5.7% over the past month, 38.6% year to date and 46% over one year, against a 52-week range of ~$79 to ~$182. The market value is ~$88 billion. That is ~22x forward earnings and ~31x trailing earnings, with a €4.00 dividend per ordinary share (a yield of roughly 2.4% at the current ADR price). Ownership is also in the news: Delfin, the Del Vecchio family holding company and EssilorLuxottica's largest shareholder, is the subject of a family contest, with Bloomberg reporting on October 29 that an heir rejected a $3.9 billion offer for a stake and MT Newswires reporting on November 2 that Citigroup is financing Leonardo Maria Del Vecchio's push to gain control of Delfin.

The bull case for ESLOY

1. AI glasses and the Meta partnership

Wearables, mainly Ray-Ban Meta and Oakley Meta glasses plus Nuance Audio, brought in ~€1.26 billion over the first nine months of 2026 and ~€486 million in the third quarter alone, now about 6.5% of quarterly revenue. Growth slowed to 20% at constant currency in the third quarter after nearly doubling in the second, and analysts at Deutsche Bank and Bernstein have pointed to a hard fourth-quarter comparison after the strong holiday 2025 season. Meta owns roughly 3% of EssilorLuxottica and supplies the software and AI, while EssilorLuxottica supplies brands, manufacturing and retail. The $799 Ray-Ban Display, with a built-in screen, is the higher-priced test of whether this line becomes a lasting category.

2. Myopia management and medtech

Stellest lenses, designed to slow the progression of short-sightedness in children, are the fastest-growing part of the lens business: the myopia portfolio grew 24% at constant currency in both the second and third quarters of 2026. Myopia is rising quickly across Asia, which helps explain why Asia-Pacific grew 15.7% in the third quarter, with double-digit gains in Greater China, India, Japan and South Korea. The company is also building a medical arm through acquisitions such as Heidelberg Engineering (diagnostic imaging) and newly consolidated eye clinics. CEO Francesco Milleri has tied a recovery in the share price to finishing this medtech shift, which carries higher margins and a more clinical, less fashion-driven customer base.

3. Retail and direct-to-consumer growth

Direct-to-consumer sales reached ~€4.09 billion in the third quarter, up 10.6% at constant currency, more than half of group revenue. Comparable-store sales grew in the high single digits, helped by Sunglass Hut, LensCrafters and Target Optical in North America and by double-digit retail growth in Italy, Spain and Turkey. Owning the store gives EssilorLuxottica the full margin on a frame and lenses sold together, and it is also the main channel for AI glasses demonstrations and fittings. E-commerce stays small at about 7% of revenue. Acquisitions such as Top Charoen in Thailand extend this model into faster-growing markets, though they add integration work and some debt.

4. Margins, cash flow and capital return

Adjusted operating margin fell to ~15.7% in 2025 and recovered to ~18.6% in the first half of 2026, as the core lens and frame business absorbed spending on AI, R&D and medical capabilities. Management's five-year outlook calls for solid revenue growth with adjusted operating profit growing broadly in line, which signals little margin expansion from here. First-half free cash flow was ~€1.07 billion. Net debt rose to ~€13.4 billion (including ~€3.9 billion of lease liabilities) from ~€10.9 billion at the end of 2025, partly from acquisitions. The €4.00 dividend carries a scrip option, and about 70% of shareholders took new shares in 2026, which kept cash out low but adds to the share count.

The bear case for ESLOY

Wearables are the largest swing factor. Growth slowed from nearly 100% in the second quarter to 20% in the third, and analysts expect a tough fourth-quarter comparison. Google has announced Gemini-powered glasses with partners including Warby Parker and Gentle Monster, and Bloomberg has reported Apple is working toward its own glasses for 2027. If smart glasses hardware becomes a commodity, EssilorLuxottica's role as Meta's manufacturer could earn less. The company also depends on Meta for the AI and software, and Meta paused Ray-Ban Display launches outside the US over supply shortages, which led Baader to downgrade the stock. US tariffs weigh on frames made in Italy and China. The dollar matters twice: North America is ~43% of revenue, so a weak dollar trims reported euro sales, and the ADR price also moves with the euro/dollar rate. The valuation (~31x trailing earnings) leaves little room for a miss. Control of Delfin, the family holding company that is the largest shareholder, is being contested among Del Vecchio heirs, and a change in who runs it could change how the group is governed. Net debt has climbed to ~€13.4 billion on acquisitions, and the scrip dividend slowly dilutes holders. French withholding tax applies to dividends paid to US ADR holders, and OTC trading in ESLOY is thinner than in the Paris shares.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding ESLOY already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on ESLOY

Too few analysts publish on ESLOY for a consensus target to mean anything, so there is no professional average to weigh against your own view. That cuts both ways: less informed opinion to lean on, and less of it already priced in. The ESLOY forecast page covers what coverage does exist.

How is ESLOY valued?

Market cap, P/E and dividend yield at today's price are in the ESLOY key stats above. The business figures below come from EssilorLuxottica's reported results as of November 2026 and change when it next reports.

  • Revenue (TTM): ~€29.3B (+5.7% latest quarter, reported)
  • Q3 2026 revenue: ~€7.49B (+7.2% constant currency)
  • Margins (TTM: gross / operating / net): ~60% / ~13% / ~8.5%
  • Net income (TTM): ~€2.5B
  • Dividend: €4.00 per share (~2.4% yield), ~€2.00 per ADR

As of November 2026: Trailing reported earnings understate the business because they include amortisation from the 2018 merger and other acquisitions; adjusted net profit was ~€3.16 billion in 2025 and ~€1.92 billion in the first half of 2026. On forward estimates the ADR trades near ~22x, down from well above 40x at the late 2025 peak and roughly in line with large European consumer health names. EV/EBITDA is ~18x on Yahoo's figures, and the price is ~3x sales. The two analysts Yahoo tracks on the ADR have a mean target of ~$132.50, well above the ~$96 close. Net debt of ~€13.4 billion is about 2x EBITDA. Each ESLOY ADR equals 0.5 ordinary shares, so the ADR price is roughly half the Paris price converted into dollars at ~$1.11 per euro.

How do you decide if ESLOY is a buy?

Whether ESLOY is a buy is easier to judge through four narrower questions:

  • Thesis: do you believe the bull case above, and is it still true today?
  • Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
  • Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
  • Overlap: check whether you already hold ESLOY indirectly through an index or sector ETF before adding more.

What would change your mind on ESLOY

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

  • Bull case breaks if: AI glasses and the Meta partnership stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
  • Bear case breaks if: wearables are the largest swing factor fails to materialise over several reporting periods while the drivers keep compounding.
  • Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the ESLOY stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about ESLOY against your real portfolio and see your actual exposure before deciding.

Your questions about EssilorLuxottica

Ask Walnut's AI anything about ESLOY and see how it fits what you own.

FAQ

Is ESLOY a good stock to buy right now?

+

That depends on which case you find more convincing, and both are on this page. The bull case rests on AI glasses and the Meta partnership, with revenue (ttm) at ~€29.3B (+5.7% latest quarter, reported). The bear case rests on wearables are the largest swing factor. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.

Should I sell ESLOY?

+

Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Wearables are the largest swing factor. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. Walnut is not an investment adviser.

What is the bull case for ESLOY?

+

AI glasses and the Meta partnership. Wearables, mainly Ray-Ban Meta and Oakley Meta glasses plus Nuance Audio, brought in ~€1.26 billion over the first nine months of 2026 and ~€486 million in the third quarter alone, now about 6.5% of quarterly revenue.

What is the bear case for ESLOY?

+

Wearables are the largest swing factor. Growth slowed from nearly 100% in the second quarter to 20% in the third, and analysts expect a tough fourth-quarter comparison. Google has announced Gemini-powered glasses with partners including Warby Parker and Gentle Monster, and Bloomberg has reported Apple is working toward its own glasses for 2027. If smart glasses hardware becomes a commodity, EssilorLuxottica's role as Meta's manufacturer could earn less. The company also depends on Meta for the AI and software, and Meta paused Ray-Ban Display launches outside the US over supply shortages, which led Baader to downgrade the stock. US tariffs weigh on frames made in Italy and China. The dollar matters twice: North America is ~43% of revenue, so a weak dollar trims reported euro sales, and the ADR price also moves with the euro/dollar rate. The valuation (~31x trailing earnings) leaves little room for a miss. Control of Delfin, the family holding company that is the largest shareholder, is being contested among Del Vecchio heirs, and a change in who runs it could change how the group is governed. Net debt has climbed to ~€13.4 billion on acquisitions, and the scrip dividend slowly dilutes holders. French withholding tax applies to dividends paid to US ADR holders, and OTC trading in ESLOY is thinner than in the Paris shares.

What does EssilorLuxottica do?

+

The world's largest eyewear company, maker of Ray-Ban and Varilux lenses, traded in the US as an ADR.

What would have to change for ESLOY to stop being worth holding?

+

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (AI glasses and the Meta partnership) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (wearables are the largest swing factor) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What is ESLOY?

+

ESLOY is the ticker for EssilorLuxottica's sponsored American Depositary Receipt, which trades over the counter in the US. EssilorLuxottica's main listing is on Euronext Paris under the symbol EL, and it is part of the CAC 40 and Euro Stoxx 50. The ADR lets US investors hold the company through an ordinary US brokerage account in dollars, without buying shares in euros on a foreign exchange. One ESLOY ADR represents half of one ordinary share, so two ADRs equal one Paris share. On November 20, 2026 the ADR closed at ~$95.79. ESLOY is quoted on the OTC market, not on the NYSE or Nasdaq, so trading volume is lower and bid/ask spreads can be wider than on the Paris listing.

How do I invest in EssilorLuxottica from the US?

+

The simplest route is to buy ESLOY through a US brokerage that supports OTC securities. Most large brokers such as Fidelity, Schwab and Interactive Brokers allow it, though some apps restrict or do not offer certain OTC ADRs, and a few may add a fee. A second route is buying the Paris-listed EL shares directly through a broker with international access, which gives deeper liquidity but means trading in euros. A third route is a fund that holds the stock, such as a Europe or Euro Stoxx 50 ETF, where EssilorLuxottica is one holding among many. Each route carries currency exposure, since the company earns and reports in euros even when the ADR is priced in dollars. Walnut can show where an ESLOY position sits in a connected portfolio but does not tell anyone whether to buy it.

What does EssilorLuxottica actually sell?

+

It sells nearly everything involved in buying glasses. On the lens side it makes Varilux progressive lenses, Crizal coatings, Transitions light-adaptive lenses and Stellest lenses for children's myopia. On the frame side it owns Ray-Ban, Oakley, Persol, Oliver Peoples, Vogue Eyewear and others, and it makes licensed eyewear for luxury houses including Chanel, Prada and Miu Miu. It runs retail chains such as LensCrafters, Sunglass Hut, Target Optical, Pearle Vision franchises and Salmoiraghi & Viganò, plus an online business and EyeMed vision insurance in the US. Newer lines include Ray-Ban Meta and Oakley Meta AI glasses, Nuance Audio hearing glasses and medical devices such as Heidelberg Engineering's diagnostic imaging. Revenue is split between Professional Solutions (selling to opticians) and Direct-to-Consumer (its own stores and websites).

Walnut is informational, not investment advice, and gives no verdict on ESLOY. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 20, 2026. Verify current figures with your broker before acting on them.

The case for and against similar stocks